



Neuroprotective effect of *Portulaca oleracea* extracts against 6-hydroxydopamine-induced lesion of dopaminergic neurons

WALESKA B. MARTINS¹, SHEYLA A. RODRIGUES¹, HATAMY K. SILVA¹, CAMILA G. DANTAS¹, WALDECY DE LUCCA JÚNIOR², LAURO XAVIER FILHO¹, JULIANA C. CARDOSO¹ and MARGARETE Z. GOMES¹

¹Instituto de Tecnologia e Pesquisa/ITP, Av. Murilo Dantas, 300, Farolândia, 49032-490 Aracaju, SE, Brasil

²Universidade Federal de Sergipe, Cidade Universitária Prof. José Aloísio de Campos, Av. Marechal Rondon, s/n, Jardim Rosa Elze, 49100-000 São Cristóvão, SE, Brasil

Manuscript received on August 3, 2015; accepted for publication on November 27, 2015

ABSTRACT

The *Portulaca oleracea* L. (Portulacaceae) is a cosmopolitan species with a wide range of biological activities, including antioxidant and neuroprotective actions. We investigated the effects of *P. oleracea* extracts in a 6-hydroxydopamine rat model of Parkinson's disease, a debilitating disorder without effective treatments. Chemical profiles of aqueous and ethanolic extracts of whole plant were analyzed by thin layer chromatography and the antioxidant activity was assessed by 2,2-diphenyl-1-picrylhydrazyl method. Male Wistar rats received intrastriatal 6-hydroxydopamine and were treated with vehicle or extracts (oral, 200 and 400 mg/kg) daily for two weeks. The behavioral open field test was conducted at days 1 and 15. Immunohistochemical analysis was performed 4 weeks after surgery to quantify tyrosine-hydroxylase cell counts in the substantia nigra pars compacta. Extracts presented antioxidant activity in concentrations above 300 µg/kg. The chromatographic analysis revealed the presence of Levodopa, alkaloids, flavonoids, saponins, tannins, terpenoids and polysaccharides. Both extracts improved motor recovery 15 days after lesion and protected from tyrosine-hydroxylase cell loss after 4 weeks, but these effects were more evident for the aqueous extract. Because the dopamine precursor is present, in addition to antioxidant compounds and neuroprotective effects, *P. oleracea* can be considered as potential strategy for treating Parkinson's disease.

Key words: Parkinson Disease, Antioxidant Response Elements, Levodopa, Purslane.

INTRODUCTION

Parkinson's disease (PD) is a neurodegenerative illness characterized by a progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc). The consequent dopamine depletion in the striatum is clinically related to

movement and cognitive disorders (Wichmann and Dostrovsky 2011). Its etiology is not fully understood, however, mechanisms of neuronal degeneration include mitochondrial dysfunction, altered proteasomal and lysosomal proteolysis, glial mediated inflammation and oxidative stress generated by lipid peroxidation, protein and DNA oxidation, and chemical and enzymatic oxidation of dopamine itself (Dexter and Jenner 2013).

Correspondence to: Margarete Zanardo Gomes
E-mail: margarete_zanardo@itp.org.br

Currently, there is no available therapy to stop or slow neurodegeneration.

Portulaca oleracea L. (*P. oleracea*) is a commonly found species and a medicinal food for human consumption. This plant, also called purslane, contains minerals, proteins, carbohydrates, β -carotene, vitamins and fatty acids (Uddin et al. 2012, 2014). Among the bioactive components and biological activities assigned to the *P. oleracea*, the presence of catecholamines (Chen et al. 2003) and its antioxidant and anti-inflammatory actions (Dkhil et al. 2011, Yue et al. 2015) deserve to be highlighted.

Neuropharmacological actions of the *P. oleracea* extracts were previously reported in rodent models. Effects included the reduction of the locomotor activity, the increase in the onset time of pentylenetetrazole-induced convulsions in mice, the opioid mediated anti-nociceptive and muscle relaxant activities in rats (Radhakrishnan et al. 2001). Biological activities also include anti-inflammatory actions (Chan et al. 2000, Lee et al. 2012).

It has been shown that *P. oleracea* protects neurons against hypoxia injury (Wanyin et al. 2012) and D-galactose induced toxicity *in vivo* (Hongxing et al. 2007). The treatment with betacyanins from *P. oleracea* improved cognitive deficits and attenuated oxidative damage induced by D-galactose in the brains of senescent mice (Wang and Yang 2010). Moreover, the *P. oleracea* extracts decreased apoptosis and oxidative-stress-induced neurodegeneration caused by the pesticide rotenone (Al-Quraishy et al. 2012, Abdel Moneim 2013).

These neuroprotective actions and the existence of dopamine and noradrenaline in extracts suggest that *P. oleracea* may be a potential candidate for the treatment of Parkinson's disease. Thus, the aim of this work was to evaluate the neuroprotective effects of the ethanolic and aqueous *P. oleracea* extracts, given orally, in animals with 6-hydroxydopamine-induced lesion of the nigrostriatal pathway, an animal model for the study of

progressive degeneration in PD. Since ethanolic and aqueous extracts are commonly studied, they were also analyzed regarding chemical profiles and antioxidant activity.

MATERIALS AND METHODS

PLANT MATERIAL

The plant material was collected in August 2012, from the greenhouse for medicinal plants at the campus of the Tiradentes University, located in Aracaju – Sergipe, Northeast of Brazil. The plant was identified by Dr. Ana Paula do Nascimento Prata and a voucher specimen (no. 20379) has been deposited at the Herbarium of the Federal University of Sergipe. The whole plant was used for the preparation of the extracts. The fresh vegetal material was manually chopped in pieces about 2 cm.

PREPARATION OF THE EXTRACTS

The aqueous extract was prepared as previously reported (Hozayen et al. 2011). The vegetal material was boiled in distilled water (80 °C, 1:1, m: v) for 60 min and then mashed with a blender apparatus (3 cycles of 15 sec). The mixture was coated (2 mm pores strainer) and lyophilized under vacuum.

The plant material was extracted with 100% ethanol (100 mL: 10 g) at room temperature, in a dark and closed container for one week. The extract was centrifuged and filtered through a Whatman number 3 filter and then concentrated using a rotary evaporator. The resultant extract was lyophilized to produce a powder (Wanyin et al. 2012).

PHYTOCHEMICAL ANALYSIS

The thin layer chromatography (TLC) was performed using n-butanol–glacial acetic acid–distilled water 7.0: 2.0: 1.0 (v/v) as mobile phase, through chamber saturation for 5 min and detect by ultraviolet (UV) light. For assessing catecholamine levels, the levodopa (D- 9628 Sigma) was used

as a positive control and the samples were diluted in hydrochloric acid (Dighe et al. 2008). The phytochemical screening was carried out using standard procedures that have been previously described (Harborne 1998): the frothing test was used for the detection of saponins, the ferric chloride test was used for the detection of tannins, the Dragendorff precipitation assay was used for the detection of alkaloids, Mg-HCl was used for the detection of flavonoids, Liebermann-Burchard and Salkowski reactions was used for the detection of triterpenes and lugol was used for the detection of polysaccharides.

QUALITATIVE AND QUANTITATIVE 2,2-DIPHENYL-1-PICRILHIDRAZILA (DPPH) FREE RADICAL SCAVENGING ACTIVITY ASSAY

The extracts were analyzed by TLC in a plate eluted in ethyl acetate and ethanol (50%:50%). After drying, a 0.4 mmol/L solution of DPPH in MeOH was added. The antioxidant activity was determined by the presence of yellow spots on a purple background (Souza et al. 2007).

The quantitative assays were performed according to the method previously described (Djouossi et al. 2015). Samples of the extracts and the positive control (trolox) were prepared in methanol (5 mg/mL) and diluted in the concentrations of 50, 100, 200, 300, 400 and 550 µg/mL. Measurement of the absorbance in the reactive mixtures (0.3 mL of sample solution with 2.7 mL DPPH solution in a 40 µg/mL concentration) was made on a 515 nm, after 40 minutes incubation at room temperature, protected from light. Absorbance values were converted in percentage of the antioxidant activity and the antioxidant efficacy was stabilized by linear regression analysis ($p < 0.05$ confidence interval). Results were expressed through µmol trolox/g-equivalent antioxidant capacity and the sufficient necessary sample concentration to scavenge 50% of DPPH radical was also estimated.

BIOLOGICAL ASSAY

Animals

Forty-eight adult male Wistar rats weighting 200–250 g were housed in a temperature controlled room (at approximately 25°C), under 12-h light/dark cycle, with free access to food and water. The experiments were carried out according to the rules of the local Animal Use and Care Committee (approval number 141110) and the Brazilian National Council for the Control of Animal Experimentation (CONCEA). Every effort was made to minimize animal suffering and to keep a number of animals used to a minimum.

Experimental design

After surgical procedures for the intrastriatal injection of 6-hydroxydopamine (6-OHDA) or saline, the animals were divided into groups ($n = 6$ per group) that received, via oral administration, vehicle (2% Tween 80 in saline), aqueous extract (AEPO) or ethanolic extract (EEPO) of *P. oleracea*, at 200 or 400 mg/kg for 15 days, consecutively. Doses were chosen based on previous work (Wanyin et al. 2012). At the first and fifteenth day after surgery, an open field test was performed in order to evaluate the motor abilities of the animals. The animals were sacrificed at 28 days following the beginning of the treatments and their brains were extracted and processed for the histological analysis.

6-OHDA microinjections

The heads of the rats were fixed on a Kopf stereotaxic instrument under general anesthesia (ketamine/xylazine, 90 and 15 mg/kg i.p.). A midline skin incision was made, exposing the skull for subsequent drilling. The neurotoxin, 6-OHDA (20 µg in 4 µl dissolved in 0.9% saline containing 0.02 mg/mL of ascorbic acid; RBI-Sigma) was injected into the right striatum with a 10 µl Hamilton syringe. The stereotaxic coordinates were 1.0 mm

anterior, 3.0 mm lateral (right side) from Bregma, and 5.0 mm ventral to the surface of the skull, with the tooth-bar set at -3.0 mm (Paxinos and Watson 1998). The microinjections were performed in a rate of $1 \mu\text{l}/\text{min}$ with an infusion pump (Insight, BR) and the needle was left in place for an additional 180 s to prevent reflux before being slowly retracted. The movement of an air bubble inside the PE-10 polyethylene tubing connecting the micro-syringe with the needle confirmed drug flow. Sham operated (control) animals were submitted to the same procedure but received ascorbate saline (0.02% ascorbic acid) instead of the neurotoxin.

The open field test

The open-field test was used to assess spontaneous locomotor activity. The following parameters evaluated during 5 mins: locomotion or crossings (number of line crosses) and rearings (the number of times the rat stood on its hind legs) (Whimbey and Denenberg 1967). The open field was made of white colored wood, and it consisted of a quadrilateral with an area of $4,830.25 \text{ cm}^2$ and walls that were 34.5 cm high, with the base subdivided into sixteen quadrants, visibly marked by black lines.

Histological analysis

Animals were euthanized in a CO_2 chamber and their brains extracted, fixed in formalin and paraffin-embedded in preparation of subsequent immunohistochemical procedures. Fifteen micrometer serial, sections were cut within a microtome (Leica). Neuroanatomical sites were identified using a rat brain atlas (Paxinos and Watson 1998). The sections were taken from -5.4 mm from Bregma to -6.0 mm). The brain sections were stained for tyrosine-hydroxylase (TH), a marker for dopaminergic neurons.

Immunohistochemistry of tyrosine-hydroxylase (TH)

For TH immunohistochemistry, the antigen recovery was carried out in citrate buffer (pH 6) by using

a microwave (3 cycles of 5 min). The endogenous peroxidase was blocked (0.3 % H_2O_2) and tissue sections were incubated 18 h with the primary antibody (rabbit anti TH: 1/1000, Pel-Freez Biologicals). Sections were processed by the streptavidin-biotin immunoperoxidase method (streptavidin HRP Kit, Dako) and immunopositive cells were visualized by addition of the chromogen 3, 3-diaminobenzidine (DAB; Sigma, 1 mg/mL) and hydrogen peroxide (0.2%). The tissue was always washed in phosphate-buffered saline between procedures. Immunopositive cells were revealed by a brown reaction product. The sections were mounted onto gelatin-coated glass slides, dehydrated in ethanol, cleared in xylene, and cover-slipped for microscopic observations. In all experiments, tissues, from every group were always processed in the same assay (Douhou et al. 2002).

Image analysis

Semi-quantitative analysis of midbrain dopaminergic cells was performed on six sections from 3 different animals. To ensure that neurons were not counted twice, counts were made using every sixth section (i.e., separated by $225 \mu\text{m}$). All the histological quantification was performed with experimenters blinded to group identity. Neurons which were positively stained exhibited labeled soma, dendrites and axons. The number of TH positive neurons in the right SNc were counted using a microscope (Nikon), equipped with a 100X objective (numerical aperture 1.4) coupled to a digital photographic camera (Nikon) and connected to a computer system. A grid ($200 \mu\text{m} \times 200 \mu\text{m}$) was overlaid, and positive cells were counted in each square using the cell counting tool of Image J NIH software. Only neurons with the whole cell body included in the square were counted. The cell density (number of positive neurons/ 0.5 mm^2 of the structure) on the side of the lesion in the experimental groups was compared with those on the unlesioned shams (Gomes et al. 2008).

Statistical analysis

Results from antioxidant activity and histological counts were expressed as percentage of controls, while the results from the open field are expressed as the mean \pm SEM. Effects of the treatments and time on behavioral tests were analyzed by two way repeated measures (MANOVA). In the case of significant interaction it was followed by one-way analysis of variance (ANOVA) and Tukey post-test. The histological and antioxidant evaluations were submitted to ANOVA followed by Tukey post-test. Values of $p < 0.05$ were considered significant. All statistical analyses were performed using SPSS for Windows (version 19.0).

RESULTS

The TLC analysis revealed the presence of three fluorescent bands, observed on the UV light at the same position. Each one corresponded to the AEPO, EEPO and levodopa positive control. In the phytochemical analysis, both extracts showed positive results for the search of alkaloids,

flavonoids, tannins, saponins, polysaccharides and terpenoids. Also, the qualitative evaluation of the extracts by TLC showed the existence of substances with antioxidant activity on both extracts.

Both AEPO and EEPO were able to sequester DPPH radicals. However, the EEPO showed antioxidant activity higher than 70% at the 500 $\mu\text{g}/\text{mL}$, while it was 52% for AEPO. The amount of extract in the samples necessary to decrease the initial concentration of the DPPH in 50% was $162.62 \pm 16.37 \mu\text{g}/\text{mL}$ for EEPO and $463.92 \pm 40.88 \mu\text{g}/\text{mL}$ for AEPO (Fig. 1). The statistical analysis (ANOVA) revealed significant differences in both the AEPO [$F_{5,30}=126.2$, $p < 0.05$] and the EEPO [$F_{5,35}=96.21$, $p < 0.05$]: For the AEPO analysis, each increment in concentration (i.e., from 50, 100, 200, 300, 400, and 500 $\mu\text{g}/\text{mL}$) produced a significant increase in its respective antioxidant activity, except that no further increase in antioxidant activity was observed from 400 to 500 $\mu\text{g}/\text{mL}$ increase in concentration (Fig. 1a). Similarly, a stepwise increase in antioxidant activity was found for nearly every increase in concentration of EEPO (Fig. 1b).




Figure 1 - Trolox-equivalent antioxidant capacity in different concentrations (50; 100; 200; 300; 400 and 500 $\mu\text{g}/\text{mL}$). Columns indicate the mean % of antioxidant activity and bars indicate the S.E.M.; the left graphic (a) presents results of the aqueous extract of *Portulaca oleracea* (AEPO), and right graphic (b) represents the ethanolic extract of *Portulaca oleracea* (EEPO) analysis. The * indicates significant difference from all the other doses under the line and # indicates significant difference between doses compared.

The MANOVA analysis of the crossings and rearing in the open field test revealed an interaction between treatment and time factors and significant differences among treatments [$F_{1,50} = 2403.84$, $p < 0.0001$ and $F_{1,50} = 802.18$, $p < 0.0001$, respectively]. Analysis of the tests conducted 24h after 6-OHDA

administration showed significant decrease in locomotion from all 6-OHDA groups compared to saline microinjections, independent of the treatment received orally (crossing: $F_{9,59} = 45.28$, $p < 0.0001$; rearing: $F_{9,59} = 14.15$, $p < 0.0001$, one-way ANOVA followed by Tukey post-test, Fig. 2). When the test




Figure 2 - Results from the open field test: Means of crossings (a and c) and rearing (b and d) at 24 h and 15 days after surgery, respectively. # indicates significant decrease from saline groups ($p < 0.001$), * indicates significant increase from 6-OHDA/vehicle with $p < 0.05$, ** indicates significant increase from 6-OHDA/vehicle with $p < 0.01$ and † indicates significant difference between doses compared ($p < 0.05$). AEPO: aqueous extract of *Portulaca oleracea*, EEPO: ethanolic extract of *Portulaca oleracea*. Columns indicate the mean and bars indicate the S.E.M.

was carried out at 15 days after surgery (Fig. 2), a significant reduction of crossing for animals treated with 6-OHDA was still observed when compared with groups which received intracerebral saline, except for 6-OHDA/AEPO 400 mg/kg. Treatments with both extracts at higher doses (6-OHDA/AEPO and 6-OHDA/EEPO 400 mg/kg) resulted in significantly higher values when compared to those obtained for the group 6-OHDA/vehicle and 6-OHDA/AEPO or 6-OHDA/EEPO 200 mg/kg. Moreover, statistical analysis revealed an increase in crossings for the 6-OHDA/AEPO 400 mg/kg compared with all other 6-OHDA groups ($F_{9,59} = 44.52$, $p < 0.0001$, one-way ANOVA followed by Tukey post-test) reaching values similar to control groups.

The mean number of rearing was also reduced in the groups that received 6-OHDA/vehicle, 6-OHDA/AEPO (200 mg/kg), 6-OHDA/EEPO (200 mg/kg) and 6-OHDA/EEPO (400 mg/kg) when compared with the groups that received intracerebral saline in 15 days. The 6-OHDA/AEPO at 400 mg/kg treatment significantly increases these values compared with all other 6-OHDA groups ($F_{9,59} = 17.00$, $p < 0.0001$). Regarding temporal analysis, both extracts of the *P. oleracea* (400 mg/kg) promoted an increase in the number of crossings (AEPO: $p = 0.001$; EEPO: $p = 0.02$) and rearings (AEPO: $p = 0.002$; EEPO: $p = 0.05$, paired t test) from 24 hours to 15 days in the lesioned animals.

The extent of the denervation in the nigrostriatal system induced by unilateral 6-OHDA microinjection was also determined by TH immunohistochemistry (Figs. 3 and 4). The 6-OHDA promoted significant decrease in the density of TH-positive neurons in the SNc, relative to the saline-microinjected counterparts ($33\% \pm 2.31$ remaining cells). The AEPO exerted protective action (200 mg/kg: $60.67\% \pm 3.57$), this effect was dose dependent (400 mg/kg: $78.17\% \pm 4.22$). The administration of EEPO at the lower dose did not modify the 6-OHDA action ($37.67\% \pm 1.38$), but the 400 mg/

kg dose promoted an increase the percentage of residual neurons ($68.5\% \pm 6.06$) similar to those observed in rats given the higher dosage of AEPO (Figs. 3 and 4, $F_{4,29} = 25.71$, $p = 0.041$).

DISCUSSION

In this study, spontaneous motor activity in the open field maze was performed 24 hours and 15 days after the administration of 6-OHDA, in order to access both initial functional symptoms and more stabilized lesion signs (Meredith et al. 2008). The 6-OHDA injections induced a significant decrease in locomotion at 24 hours, corroborating the findings of other authors (Dauer and Przedborski 2003, Truong et al. 2006). After 15 days, these effects were attenuated in a dose dependent manner in the 6-OHDA-treated rats given AEPO and EEPO. Results of immunohistochemistry are compatible with these observations, since the tyrosine-hydroxylase




Figure 3 - Percentages of tyrosine-hydroxylase positive cell density (TH+) in the substantia nigra pars compacta (SNc), 28 days after surgery, from saline microinjected rats. Different number of asterisks indicates statistical difference between groups ($p < 0.05$) while equal characters indicate similar results. AEPO: aqueous extract of *Portulaca oleracea*, EEPO: ethanolic extract of *Portulaca oleracea*. Columns indicate the mean and bars indicate the S.E.M. ($n = 6$ per group).




Figure 4 - Photomicrographs of tyrosine-hydroxylase positive neurons (TH+) in the substantia nigra pars compacta (SNc) of rats, 28 days after surgery. **a**: saline microinjected and treated with vehicle; **b**: 6-hydroxydopamine microinjected and treated with vehicle; **c** and **d**: 6-hydroxydopamine microinjected and treated with aqueous extract (AEPO) or ethanolic extract (EEPO) of *Portulaca oleracea* at 400 mg/kg, respectively. Magnifications of 100X.

is the enzyme that catalyzes the rate-limiting step in the synthesis of catecholamines and a marker for dopaminergic reminiscent neurons (Daubner et al. 2011). Here, the administration of both extracts produced a nearly 70% increase in preservation of dopaminergic cells. It is in agreement with the reports that spontaneous locomotion, measured in an open field, is impaired in a manner closely related to striatal dopamine depletion after 6-OHDA in rodents (Kirik et al. 1998, Willard et al. 2015).

Our data indicate that *P. oleracea* contains bioactive compounds that are able to exert a protective effect against degeneration of dopaminergic neurons. It has already been demonstrated in

the rotenone model of PD that aqueous extracts of *P. oleracea* protects the rat brain from oxidative stress through a decrease in the levels of glutathione (Al-Quraishy et al. 2012). Also, the biochemical changes, including an increase in the intercellular content of calcium and dopamine metabolites and decrease in the complex I activity, as well as apoptosis induced by rotenone in the rat striatum, were effectively counteracted by administration of *P. oleracea* (Abdel Moneim et al. 2012, Abdel Moneim 2013).

As a catecholaminergic neurotoxin, 6-OHDA, when applied into rat striatum, induces a slow degenerative process in dopaminergic neurons. One

of the underlying mechanisms of cell death is oxidative stress, which has gained special attention because of its association with the reported H_2O_2 and free radical formation, decreased superoxide dismutase (SOD) activity, increased monoaminoxidase (MAO) activity and mitochondrial complex toxicity (Martínez-Cerdeño et al. 2010, Decressac et al. 2012).

Both aqueous (Hongxing et al. 2007, Al-Quraishy et al. 2012) and ethanolic (Wanyin et al. 2012) *P. oleracea* extracts have demonstrated protective effects against oxidative stress-related pathologies. For example, the oral administration of EAPO significantly increased the activities of antioxidant enzymes, such as SOD and decreased the production of MAO (Dkhil et al. 2011). In agreement with previous reports, our results from the DPPH test confirm the antioxidant activity of both types of *P. oleracea* extracts. The possible neuroprotection mechanism could be related to this antioxidant activity (Molyneux 2004, Chen et al. 2009), since both extracts in concentrations above 300 μ g/kg dose provided 50% of the antioxidant effects of ascorbic acid. It is interesting to note that *P. oleracea* ethanolic crude extract did not present toxic effect on normal mice even at 500 mg/kg (Aljeboori et al. 2014).

The antioxidant action of *P. oleracea* extracts can be attributed to its constituents. It has been reported the presence of gallotannins, omega-3 fatty acids, ascorbic acid, α -tocopherols, kaempferol, quercetin, and apigenin (Yan et al. 2012). The analysis of the extracts showed the presence of alkaloids, flavonoids, tannins, saponins, terpenoids and polysaccharides. The same compounds were found in other studies concerning *P. oleracea* chemical composition (Lu et al. 2009, Dong et al. 2010, Zhu et al. 2010, Uddin et al. 2012, Tian et al. 2014, Liang et al. 2014). The consumption of foods rich in flavonoids is associated with several beneficial effects for human health and can reduce the risk of developing PD in humans (Gao et al.

2012). Also, the alkaloids compounds betacyanins, soluble pigments found in *P. oleracea*, had neuroprotective effects in senescent mice, reducing the levels reactive oxygen species damage and lipid peroxidation (Wang and Yang, 2010).

In addition, the tannins demonstrated a strong antioxidant activity (Figueroa-Espinoza et al. 2015), polysaccharides of *P. oleracea* exhibited free radical scavenging activities and protective effect against oxidative damage (Chen et al. 2009), and terpenoids also exerted a neuroprotective role against neuronal hypoxia (Zhu et al. 2007). Also, previous work showed that AEPO can modulate the activity of acetylcholinesterase (Yang et al. 2012) and increase the monoamine contents due its melatonin, omega-3 fatty acids, flavonoids and phenolic compounds (Abdel Moneim et al. 2012).

The group of flavonoids possesses important biological activities and kaempferol and apigenin have been found in ethanolic extracts of leaves and stems (Xu et al. 2006, Zhu et al. 2010). It may explain the higher antioxidant activity of EEPO. On the other hand, AEPO was more effective against 6-OHDA deleterious effects and it suggests that neuroprotection could have been mediated by a mechanism other than oxidative stress.

The TLC analysis revealed the occurrence of a fluorescent band at the same position of levodopa in both extracts. Catecholamines, such as dopamine, are synthesized from levodopa precursor by tyrosine-hydroxylase and have important roles as neurotransmitters in the central nervous system and in PD, once the dopamine depletion is the responsible for the hallmark symptoms of disease (Missale et al. 1998). The presence of catecholamines such as dopamine has been reported in *P. oleracea* (Gandía-Herrero et al. 2009, Weng et al. 2005) as well as the presence of levodopa in *P. oleracea* and the ability of converting tyrosine to levodopa (Harris et al. 2012).

Considering the importance of levodopa as standard treatment in PD and the fact the antioxidant substances can reduce levodopa-induced

dyskinesia (Del Bel et al. 2014, Padovan-Neto et al. 2009), futures studies are needed to explore the potential of *P. oleracea* in dopamine replacement therapy. From our results, in addition to the antioxidant effects, the improvement in behavioral performance promoted by *P. oleracea* could be explained, at least in part, by some dopaminergic-like action.

In conclusion, the present results indicated that aqueous and ethanolic extracts of *P. oleracea* were able to reverse the behavioral motor deficits and neuronal loss induced by 6-OHDA and that these effects may be related to their antioxidant activity and bioactive compounds. The *P. oleracea* is, therefore, an important target of study with therapeutic potential for the treatment of neurodegenerative diseases.

ACKNOWLEDGMENTS

The authors thank to the Fundação de Apoio à Pesquisa e à Inovação Tecnológica do Estado de Sergipe (FAPITEC-SE), Grant number 04/2011.

REFERENCES

- ABDEL MONEIM AE. 2013. The neuroprotective effects of purslane (*Portulaca oleracea*) on rotenone-induced biochemical changes and apoptosis in brain of rat. *CNS Neurol Disord Drug Targets* 12: 830-841.
- ABDEL MONEIM AE, NASR IA, DKHIL MA AND AL-QURAI SHY S. 2012. Neuronal activities of *Portulaca oleracea* in adult rats. *J Med Plants Res* 6: 3162-3168.
- AL-QURAI SHY S, DKHIL MA AND MONEIM AE. 2012. Protective effects of *Portulaca oleracea* against rotenone mediated depletion of glutathione in the striatum of rats as an animal model of Parkinson's disease. *Pestic Biochem Physiol* 103: 108-114.
- ALJEBOORI KH, AL-RUBAI OH AND NAHI YY. 2014. Study of pathological effects of crude extract of *Portulaca oleracea* L. in the albino mice organs. *Int J Technol Res Applications* 2: 29-32.
- CHAN K, ISLAM MW, KAMIL M, RADHAKRISHNAN R, ZAKARIA MN, HABIBULLAH M AND ATTAS A. 2000. The analgesic and anti-inflammatory effects of *Portulaca oleracea* L. subsp. *Sativa* (Haw.) Celak. *J Ethnopharmacol* 73: 445-451.
- CHEN CJ, WANG WY, WANG XL, DONG LW, YUE YT, XIN HL, LING CQ AND LI M. 2009. Anti-hypoxic activity of the ethanol extract from *Portulaca oleracea* in mice. *J Ethnopharmacol* 124: 246-250.
- CHEN J, SHI YP AND LIU JY. 2003. Determination of noradrenaline and dopamine in Chinese herbal extracts from *Portulaca oleracea* L. by high-performance liquid chromatography. *J Chromatogr A* 1003: 127-132.
- DAUBNER SC, LE T AND WANG S. 2011. Tyrosine hydroxylase and regulation of dopamine synthesis. *Arch Biochem Biophys* 508: 1-12.
- DAUER W AND PRZEDBORSKI S. 2003. Parkinson's disease: Mechanisms and models. *Neuron* 39: 889-909.
- DECRESSAC M, MATTSSON B AND BJÖRKLUND A. 2012. Comparison of the behavioural and histological characteristics of the 6-OHDA and α -synuclein rat models of Parkinson's disease. *Exp Neurol* 235: 306-315.
- DEL BEL E, PADOVAN-NETO FE, SZAWKA RE, DA SILVA CA, RAISMAN-VOZARI R, ANSELMO-FRANCI J, ROMANO-DUTRA AC AND GUIMARAES FS. 2014. Counteraction by nitric oxide synthase inhibitor of neurochemical alterations of dopaminergic system in 6-OHDA-lesioned rats under L-DOPA treatment. *Neurotox Res* 25: 33-44.
- DEXTER DT AND JENNER P. 2013. Parkinson disease: from pathology to molecular disease mechanisms. *Free Radic Biol Med* 62: 132-144.
- DIGHE V, DHOTRE O, PAREKH G AND GURSALE A. 2008. Quantification of dopamine in *Portulaca oleracea* Linn. by high-performance thin-layer chromatography. *J Plan Chromatogr* 21: 183-186.
- DJOUSSIMG, TAMOKOU JD, NGNOKAMD, KUIATE JR, TAPONDJOU LA, HAKAT D AND VOUTQUENNE-NAZABADIOKO L. 2015. Antimicrobial and antioxidant flavonoids from the leaves of *Oncoba spinosa* Forssk. (Salicaceae). *BMC Complement Altern Med* 28: 15-134.
- DKHIL AM, MONEIM AE, AL-QURAI SHY S AND SALEH RA. 2011. Antioxidant effect of purslane (*Portulaca oleracea*) and its mechanism of action. *J Med Plant Res* 5: 1589-1563.
- DONG CX, HAYASHI K, LEE JB AND HAYASHI T. 2010. Characterization of structures and antiviral effects of polysaccharides from *Portulaca oleracea* L. *Chem Pharm Bull* 58: 507-510.
- DOUHOU A, DEBEIR T, MURER MG, DO L, DUFOUR N, BLANCHARD V, MOUSSAOUI S, BOHME GA, AGID Y AND RAISMAN-VOZARI R. 2002. Effect of chronic treatment with riluzole on the nigrostriatal dopaminergic system in weaver mutant mice. *Exp Neurol* 176: 247-253.
- FIGUEROA-ESPINOZA MC, ZAFIMAHOVA A, ALVARADO PG, DUBREUCQA E AND PONCET-LEGRAND C. 2015. Grape seed and apple tannins: emulsifying and antioxidant properties. *Food Chem* 178: 38-44.
- GANDÍA-HERRERO F, JIMÉNEZ-ATIÉNZA M, CABANES J, ESCRIBANO J AND GARCÍA-

- CARMONA F. 2009. Fluorescence detection of tyrosinase activity on dopamine-betaxanthin purified from *Portulaca oleracea* (common purslane) flowers. *J Agric Food Chem* 57: 2523-2528.
- GAO X, CASSIDY A, SCHWARZSCHILD MA, RIMM EB AND ASCHERIO A. 2012. Habitual intake of dietary flavonoids and risk of Parkinson disease. *Neurology* 78: 1138-1145.
- GOMES MZ, RAISMAN-VOZARI R AND DEL BEL EA. 2008. A nitric oxide synthase inhibitor decreases 6-hydroxydopamine effects on tyrosine hydroxylase and neuronal nitric oxide synthase in the rat nigrostriatal pathway. *Brain Res* 1203: 160-169.
- HARBORNE JB. 1998. *Phytochemical Methods: a guide to modern techniques of plant analysis*. 3rd ed., London, UK: Published by Chapman and Hall, 278 p.
- HARRIS NN, JAVELLANA J, DAVIES KM, LEWIS DH, JAMESON PE, DEROLES SC, CALCOTT KE, GOULD KS AND SCHWINN KE. 2012. Betalain production is possible in anthocyanin-producing plant species given the presence of DOPA-dioxygenase and L-DOPA. *BMC Plant Biol* 12: 34.
- HONGXING Z, NANCAI Y, GUOFU H, JIANBO S, YANXIA W, HANJU H, QIAN L, WEI M, YANDONG Y AND HAO H. 2007. Neuroprotective effects of purslane herb aqueous extracts against D-galactose induced neurotoxicity. *Chem Biol Interact* 170: 145-152.
- HOZAYEN W, BASTAWY M AND ELSHAFFEY H. 2011. Effects of Aqueous Purslane (*Portulaca Oleracea*) Extract and Fish Oil on Gentamicin Nephrotoxicity in Albino Rats. *Nat Sci* 9: 47-62.
- KIRIK D, ROSENBLAD C AND BJORKLUND A. 1998. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. *Exp Neurol* 152: 259-277.
- LEE S, KIM JS, LEE YJ, KANG DG AND LEE HS. 2012. Anti-TNF- α activity of *Portulaca oleracea* in vascular endothelial cells. *Int J Mol Sci* 13: 5628-5644.
- LIANG X, TIAN J, LI L, GAO J, ZHANG Q, GAO P AND SONG S. 2014. Rapid determination of eight bioactive alkaloids in *Portulaca oleracea* L. by the optimal microwave extraction combined with positive-negative conversion multiple reaction monitor (+/-MRM) technology. *Talanta* 120: 167-172.
- LU JR, HE TR AND PUTHETI R. 2009. Compounds of Purslane extracts and effects of antikinetic fatigue. *J Med Plants Res* 3: 506-510.
- MARTÍNEZ-CERDEÑO V, NOCTOR SC, ESPINOSA A, ARIZA J, PARKER P, ORASJI S, DAADI MM, BANKIEWICZ K, ALVAREZ-BUYLLA A AND KRIEGSTEIN AR. 2010. Embryonic MGE precursor cells grafted into adult rat striatum integrate and ameliorate motor symptoms in 6-OHDA-lesioned rats. *Cell Stem Cell* 6: 238-250.
- MEREDITH GE, SONSALLA P AND CHESSELET MF. 2008. Animal Models of Parkinson's Disease Progression. *Acta Neuropathol* 115: 385-398.
- MISSALE C, NASH S, ROBINSON S, JABER M AND CARON MG. 1998. Dopamine receptors: from structure to function. *Physiol Rev* 78: 189-225.
- MOLYNEUX P. 2004. The use of the stable free radical diphenylpicrylhydrazyl (DPPH) for estimating antioxidant activity. *J Sci Tech* 26: 211-219.
- PADOVAN-NETO FE, ECHEVERRY MB, TUMAS V AND DEL BEL EA. 2009 Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. *Neuroscience* 159: 927-935.
- PAXINOS G AND WATSON C. 1998. *The Rat Brain in Stereotaxic Coordinates*. 4th ed., New York, USA: Academic Press, 120 p.
- RADHAKRISHNAN R, ZAKARIA MN, ISLAM MW, CHEN HB, KAMIL M, CHAN K AND AL-ATTAS A. 2001. Neuropharmacological actions of *Portulaca oleracea* L. v. sativa (Hawk). *J Ethnopharmacol* 76: 171-176.
- SOUZA CM ET AL. 2007. Total phenols and antioxidant activity of five medicinal plants. *Quim Nova* 30: 351-355.
- TIAN JL, LIANG X, GAO PY, LI DQ, SUN Q, LI LZ AND SONG SJ. 2014. Two new alkaloids from *Portulaca oleracea* and their cytotoxic activities. *J Asian Nat Prod Res* 16: 259-264.
- TRUONG L, ALLBUTTH, KASSIOU M AND HENDERSON JM. 2006. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. *Behav Brain Res* 169: 1-9.
- UDDIN MK, JURAIMI AS, ALI ME AND ISMAIL MR. 2012. Evaluation of Antioxidant Properties and Mineral Composition of Purslane (*Portulaca oleracea* L.) at Different Growth Stages. *Int J Mol Sci* 13: 10257-10267.
- UDDIN MK, JURAIMI AS, HOSSAIN MS, NAHAR MA, ALI ME AND RAHMAN MM. 2014. Purslaneweed (*Portulaca oleracea*): a prospective plant source of nutrition, omega-3 fatty acid, and antioxidant attributes. *Sci World J*. Available at: <http://www.hindawi.com/journals/tswj/2014/951019/>. Accessed on April 15, 2015. Article ID 951019.
- WANG CQ AND YANG GQ. 2010. Betacyanins from *Portulaca oleracea* L. ameliorate cognition deficits and attenuate oxidative damage induced by D-galactose in the brains of senescent mice. *Phytomedicine* 17: 527-553.
- WANYIN W, LIWEI D, LIN J, HAILIANG X, CHANGQUAN LAND MIN L. 2012. Ethanol extract of *Portulaca oleracea* L. protects against hypoxia-induced neuro damage through modulating endogenous erythropoietin expression. *J Nutr Biochem* 23: 385-391.
- WENG Q, YUANK, ZHANGH, XIONGJ, WANGC AND XU G. 2005. Determination of dopamine and norepinephrine in *Portulaca oleracea* L. by micellar electro kinetic

- capillary chromatography with amperometric detection. *Se Pu* 23: 18-21.
- WHIMBEY AE AND DENENBERG VH. 1967. Two independent behavioral dimensions in open-field performance. *J Comp Physiol Psychol* 63: 500-504.
- WICHMANN T AND DOSTROVSKY JO. 2011. Pathological basal ganglia activity in movement disorders. *Neuroscience* 198: 232-244.
- WILLARD AM, BOUCHARD RS AND GITTIS AH. 2015. Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice. *Neuroscience* 301: 254-267.
- XU X, YU L AND CHEN G. 2006. Determination of flavonoids in *Portulaca oleracea* L. by capillary electrophoresis with electrochemical detection. *J Pharm Biomed Anal* 41: 493-499.
- YAN J, SUN LR, ZHOU ZY, CHEN YC, ZHANG WM, DAI HF AND TAN JW. 2012. Homoisoflavonoids from the medicinal plant *Portulaca oleracea*. *Phytochemistry* 80: 37-41.
- YANG Z, ZHANG D, REN J, YANG M AND SHUO L. 2012. Acetylcholinesterase inhibitory activity of the total alkaloid from traditional Chinese herbal medicine for treating Alzheimer's disease. *Med Chem Res* 21: 734-738.
- YUE T, XIAOSA W, RUIRUI Q, WENCAI S, HAILIANG X AND MIN L. 2015. The Effects of *Portulaca oleracea* on Hypoxia-Induced Pulmonary Edema in Mice. *High Alt Med Biol* 16: 43-51.
- ZHU H, WANG Y, LIU Y, XIA Y AND TANG T. 2010. Analysis of Flavonoids in *Portulaca oleracea* L. by UV-Vis Spectrophotometry with Comparative Study on Different Extraction Technologies. *Food Anal Meth* 3: 90-97.
- ZHU L, WU XM, YANG L, DU F AND QIAN ZM. 2007. Up-regulation of HIF-1 α expression induced by ginkgolides in hypoxic neurons. *Brain Res* 1166: 1-8.